Author: Daniel A. Saez, MSc, Manager, LungMATCH Navigation Program, GO2 for Lung Cancer People with lung cancer receiving treatment may encounter acquired drug resistance—a reduction in treatment effectiveness over time. Tagrisso (osimertinib) is currently a frontline treatment for people [...]
Author: Daniel A. Saez, MSc, Manager, LungMATCH Navigation Program, GO2 for Lung Cancer Immunotherapy, a type of treatment that helps the body’s own immune system fight cancer, is often discussed as a first line of treatment for people with [...]
On March 4th, 2022, the Food and Drug Administration (FDA) approved Opdivo (nivolumab) for treatment before surgery in combination with platinum-based chemotherapy in patients with stage IB to IIIA non-small cell lung cancer (NSCLC). The approval was based on [...]
Author: Everett Moding, MD, PhD, Assistant Professor Department of Radiation Oncology, Stanford University School of Medicine A combination of chemotherapy and radiation therapy (chemoradiation therapy) is the backbone of treatment for non-small cell lung cancer (NSCLC) that has spread [...]
I was diagnosed with stage IV NSCLC adenocarcinoma on November 3, 2017 and found out I was ALK positive on November 26. Being diagnosed with lung cancer came as a total shock, especially since I am a non-smoker. My [...]
Author: Rashmi Acharya, MS, Science and Research Specialist, GO2 for Lung Cancer The 2021 World Conference on Lung Cancer (WCLC) had multiple researchers presenting their findings on broad areas of research in early-stage lung cancer. These presentations bring highly [...]
Authors: Daniel A. Saez, MSc, Treatment and Trials Navigator, GO2 for Lung Cancer and Jacinta R. Wiens, PhD, Director of Lung Cancer Registry, GO2 for Lung Cancer The World Conference on Lung Cancer (WCLC) highlighted many up-and-coming treatments for [...]
On October 15th, 2021, the Food and Drug Administration (FDA) approved Tecentriq (atezolizumab) for treatment following surgery and platinum-based chemotherapy in patients with stage II to IIIA non-small cell lung cancer (NSCLC) whose tumors have PD-L1 expression ≥ 1% as determined by a FDA-approved test. The [...]
Don’t miss our deep dive on topics presented at IASLC's 2021 World Conference on Lung Cancer, including presentations from our very own GO2 for Lung Cancer Science and Research Team. Subscribe to our Magnifying LeNS newsletter and look out [...]
I was diagnosed with stage IV adenocarcinoma of the lung on September 7, 2020. There have been many times since being diagnosed that I have said to myself (and others) that I am lucky for my diagnosis. Lucky with [...]